The epicutaneous immunotherapy company OK FR DBV TECHNOLOGIES VIASKIN® PRODUCTS EPICUTANEOUS IMMUNOTHERAPY (EPIT®) VIASKIN® TECHNOLOGY INVESTOR RELATIONS NEWS & EVENTS We are committed to finding a safe, effective, and patient-friendly therapy for food and pediatric allergy patients OLFUS-VIPES Results LATEST NEWS 11/17/2016 DBV Technologies, BioNet-Asia and Geneva University Hospitals Complete Dosing in First Cohort of Phase I Study of Viaskin rPT for Booster Vaccination Against Pertussis Download the PDF (347KB) 11/12/2016 DBV Technologies Announces Poster Presentations at the 2016 American College of Allergy, Asthma, and Immunology Meeting Download the PDF (1.1MB) DOCUMENTATION 04/28/2016 20-F Form 2015 Download PDF (1.9MB) AGENDA November 16-17, 2016 Jefferies London Healthcare Conference the Waldorf Hilton in London, UK Scientific congresses March 3 - 6, 2017 2017 AAAAI Annual Meeting (American Academy of Allergy, Asthma and Immunology) Atlanta, USA June 17 - 21, 2017 EAACI (European Academy Allergy and Clinical Immunology) Conference Helsinki, Finland EAACI Congress 2016 The EAACI (European Academy Allergy and Clinical Immunology) Congress took place in Vienna from June 11th to 15th. SCIENTIFIC ABSTRACTS Epicutaneous Immunotherapy ABOUT US Follow us Share Contact DBV Technologies Office Headquarters 177-181 avenue Pierre Brossolette 92120 – Montrouge France Phone: +33 (0)1 55 42 78 78 Google Maps CONTACT FORM US Office 320 Park Avenue New York, NY 10022 United States Phone: +1-212-271-0863 Google Maps © DBV Technologies 2014 Credits Term of use Cookies Contact Site map Recruitments